Patents Examined by Michael Pak
  • Method of treating colorectal cancer tumor
    Patent number: 8535670
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventor: Somasekar Seshagiri
  • Angiogenesis promoted by caged growth factors
    Patent number: 8492339
    Abstract: The present disclosure relates to controlling the release of growth factors for the promotion of angiogenesis. The growth factors or a polymer matrix are modified by photoactive compounds, such that the growth factors are not released into an active form until they are irradiated with light. The disclosure also relates to tissue engineering scaffolds comprising one or more polymers and at least two growth factors.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: July 23, 2013
    Assignee: Empire Technology Development LLC
    Inventor: Seth Adrian Miller
  • Formulation comprising GLP-1
    Patent number: 8492330
    Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: July 23, 2013
    Assignee: Emisphere Technologies, Inc.
    Inventors: Mohammed Amin Khan, Bryan Edward Jones, John McNeill McGill
  • Modified soluble FGF receptor Fc fusions method
    Patent number: 8481487
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 9, 2013
    Assignee: Aventis Pharma S.A.
    Inventors: Francis Blanche, Béatrice Cameron, Sylvie Sordello, Céline Nicolazzi, Marc Trombe, Mark Nesbit
  • Anti-IGF-IR antibodies and uses thereof
    Patent number: 8444982
    Abstract: The subject invention provides antibodies, or binding fragments thereof, that specifically bind to human IGF-IR. Also provided are nucleic acid molecules encoding the antibodies and binding fragments of the subject invention and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: May 21, 2013
    Assignee: The University of Hong Kong
    Inventor: Mei-Yun Zhang
  • Ion channel assay methods
    Patent number: 8426201
    Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: April 23, 2013
    Assignee: Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Michael P. Maher, Jesus E. Gonzalez, III
  • RORS as modifiers of the p21 pathway and methods of use
    Patent number: 8426147
    Abstract: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: April 23, 2013
    Assignee: Exelixis, Inc.
    Inventors: Helen Francis-Lang, Lori Friedman, Thomas Kidd, Siobhan Roche, Haiguang Zhang
  • Method for detecting invasive microvesicles derived from tumor cells
    Patent number: 8420334
    Abstract: The present application relates to the isolation and analysis of populations of microvesicles, such as populations of microvesicles that are shed by tumor cells and contain the protein ARF6. Invasive microvesicles from tumor cells contain a variety of specific proteins, including ARF6.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: April 16, 2013
    Assignee: University of Notre Dame
    Inventors: Crislyn D'Souza-Schorey, James W. Clancy, Vandhana Muralidharan-Chari
  • Lipoparticles comprising ion channels, methods of making and using the same
    Patent number: 8377691
    Abstract: The present invention relates to the use of lipoparticles, virus-like particles, and viruses. The present invention also relates to testing ion channel function and modulators of ion channels.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: February 19, 2013
    Assignee: Integral Molecular, Inc.
    Inventor: Benjamin J. Doranz
  • Polypeptides, antibody variable domains and antagonists methods for
    Patent number: 8357780
    Abstract: The invention relates to anti-IL-1R1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: January 22, 2013
    Assignee: Domantis Limited
    Inventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
  • Isoforms of human somatostatin receptor type 5
    Patent number: 8354273
    Abstract: The present invention concerns two human nucleic acids comprising sequences which code two novel isoforms of human somatostatin receptor type 5 produced by alternative adjustment, called sst5B and sst5C and with possible uses in tumoral processes. Additionally, the invention concerns oligonucleotide pairs used for the differential detection of said isoforms by means of the PCR technique in different tissues.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: January 15, 2013
    Assignee: Universidad de Cordoba
    Inventors: Mario Durán Prado, Antonio Jesús Martínez Fuentes, Rafael Vazquez Martínez, Socorro García Navarro, María del Mar Malagón Poyato, Justo Pastor Castaño Fuentes, Francisco Garcia-Navarro
  • Anti-alpha5/beta1 antibody
    Patent number: 8350010
    Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: January 8, 2013
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye
  • Intracellular DNA receptor
    Patent number: 8334101
    Abstract: Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: December 18, 2012
    Assignee: University of Massachusetts
    Inventors: Eicke Latz, Veit Hornung, Katherine A. Fitzgerald
  • High throughput assay for discovering new inhibitors of the GIRK1/4 channel
    Patent number: 8323911
    Abstract: In certain embodiments of the present disclosure, a method for determining an inhibitor of acetylcholine-activated potassium channel is described. The method includes incubating a cardiac cell in a solution comprising a test compound. The method further includes adding a muscarine (M2) receptor agonist to the cardiac cell in the solution and monitoring the cardiac cell for a change in membrane potential. A statistically insignificant change in the membrane potential following addition of the muscarine (M2) receptor to the solution signifies that the test compound is a K+ channel blocker that inhibits opening of the acetylcholine-activated potassium channel.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: December 4, 2012
    Assignee: University of South Carolina
    Inventor: Kenneth B. Walsh
  • DNA-damage-induced proteolysis
    Patent number: 8318446
    Abstract: The present application provides methods for identifying compounds for inhibiting DNA damage-induced Htt proteolysis, and methods and compositions for protecting cells from DNA damage-induced cleavage of Htt.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: November 27, 2012
    Assignee: California Institute of Technology
    Inventors: Ali Khoshnan, Paul H Patterson
  • Assay for detection of transient intracellular CA
    Patent number: 8304198
    Abstract: This invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+ channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of ?-CaMKll as a chimera with green fluorescent protein (GFP-?-CaMKII) or its mutants as described herein.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: November 6, 2012
    Assignees: Rajiv Gandhi Centre for Biotechnology, Department of Biotechnology
    Inventors: Vyomakesannair Ramakrishnapillai Omkumar, Rajeev Kumar Raveendran, Mathew Steephan, Mayadevi Madhavan, Suma Priya Sudarsanadevi
  • Treating stroke and other diseases without inhibiting N-type calcium channels
    Patent number: 8288345
    Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: October 16, 2012
    Assignee: Nono, Inc.
    Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
  • Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors
    Patent number: 8241863
    Abstract: The present invention relates to a method of screening for a compound that regulate SUMOylation of the nuclear receptor proteins comprising contacting the compound of interest to the nuclear receptor protein, and detecting SUMOylation of the nuclear receptor protein, thereby screening for a compound that regulates SUMOylation.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: August 14, 2012
    Assignee: The Regents of the University of California
    Inventors: Gabriel Pascual, Christopher K. Glass, Michael G. Rosenfeld
  • EGFR mutations
    Patent number: 8232062
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: July 31, 2012
    Assignee: Genetech, Inc.
    Inventor: Somasekar Seshagiri
  • H-gated ion channel
    Patent number: 8232063
    Abstract: The invention relates to an isolated or recombinant Na+/H+ exchanger comprising an isolated or recombinant Na+/H+ exchanger, particularly to the PBO-4 Na+/H+ exchanger. Also disclosed is an isolated or recombinant protein component of an H+-gated channel which can be affected by extracellular Ca2+ concentration. In particular, the invention relates to PBO-5 and/or PBO-8 and/or a H+-gated channel composed of PBO-5 and PBO-8. The invention relates to compounds isolated from a vertebrate organism, wherein said compounds comprise at least a part of a H+-gated channel or Na+/H+ exchanger. The invention also relates to a method for identifying a component of a H+-gated channel in a vertebrate organism.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: July 31, 2012
    Assignee: University of Utah Research Foundation
    Inventors: Erik M. Jorgensen, Asim A. Beg, Paola Nix